Avimer Bio, a California-based biotechnology company, in collaboration with structural biologists at the Spanish National Cancer Research Centre (CNIO), announced on Thursday a new publication in the Journal of the American Chemical Society (JACS) describing advances in building self-assembling protein cages with atomic precision.
Avimer Bio said the study addresses the challenge of creating predictable protein architectures when building blocks bend during assembly. The team developed algorithms that forecast how alpha-helical protein segments flex, enabling designers to use natural molecular flexibility. This produced cubic protein cages formed from four trimeric protein blocks, twelve subunits in total, with molecular masses above 600 kilodaltons and stability in solution.
High-resolution cryo-electron microscopy at CNIO confirmed that the physical structures matched computational models, with resolutions of 3.0 to 3.9 angstroms and backbone deviations as low as 2 angstroms. The data validated the predicted helix-bending patterns.
The designed cages can present multiple therapeutic proteins in controlled arrangements to cluster cell receptors, supporting applications in autoimmune diseases such as rheumatoid arthritis and ulcerative colitis, and in oncology where receptor grouping can stimulate immune responses against tumours.
The platform relies on minimal changes to natural protein sequences and uses a single type of protein subunit per cage, simplifying production and supporting evaluation of immune response.
XtalPi submits US FDA IND application for KQTD-126 in chronic intestinal pain
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
Altesa BioSciences presents positive vapendavir clinical data at ERS International Congress 2026
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
Teva reports positive Phase 2a data for TEV '408 in celiac disease
AbbVie seeks EMA approval for subcutaneous induction of risankizumab in Crohn's disease
AstraZeneca and Amgen report Tezspire met primary endpoints in Phase III EoE trial
Oxcia receives EMA orphan designation for OXC-201 in idiopathic pulmonary fibrosis
Graviton BioScience reports positive trial results for GV101 in chronic Graft versus Host Disease
Cellenkos' CK0803 granted US FDA Fast Track designation for ALS
European Commission grants orphan designation for Vanda's imsidolimab
CureGene commences dosing in Phase I trial of CG-0416
Genetic Analysis launches microbiome test at Centre for Digestive Diseases in Sydney
Can-Fite reports preclinical data supporting Phase IIb pancreatic cancer study
AlzeCure completes QuantumCell transaction with USD12m upfront payment